The Axillary Hyperhidrosis drugs in development market research report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Axillary Hyperhidrosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Axillary Hyperhidrosis by nine companies/universities/institutes. The top development phase for Axillary Hyperhidrosis is phase i with three drugs in that stage. The Axillary Hyperhidrosis pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Axillary Hyperhidrosis pipeline products market are: Viatris, Kaken Pharmaceutical and Dr. August Wolff GmbH & Co KG Arzneimittel.

The key targets in the Axillary Hyperhidrosis pipeline products market include Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM), Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), and Muscarinic Acetylcholine Receptor M3 (CHRM3).

The key mechanisms of action in the Axillary Hyperhidrosis pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with three drugs in Phase III. The Axillary Hyperhidrosis pipeline products include five routes of administration with the top ROA being Topical and three key molecule types in the Axillary Hyperhidrosis pipeline products market including Protein, and Small Molecule.

Axillary Hyperhidrosis overview

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery, and antiperspirants.

For a complete picture of Axillary Hyperhidrosis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.